A 2022 study reported missense mutations in ADCK2 in 9.4% of breast cancer patients, whereas such mutations were relatively rare in studies of other cancers, occurring in 0–1% of endometrial carcinomas and up to 3.5% of uterine carcinomas. This evidence concerns the gene ADCK2 and cancer.